Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisH

Patients receiving intravenous bisphosphonates should avoid invasive dental procedures

Eric Wooltorton
CMAJ June 21, 2005 172 (13) 1684; DOI: https://doi.org/10.1503/cmaj.050640
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Reason for posting: The intravenous bisphosphonates pamidronate (Aredia) and zoledronic acid (Zometa) are often used to treat cancer-related hypercalcemia, Paget's disease and symptoms from solid-tumour bone metastases and osteolytic lesions of multiple myeloma. However, since 2003, osteonecrosis of the jaw has been reported in at least 217 patients taking the drugs,1 often soon after procedures such as tooth extraction.2 In light of this, the US Food and Drug Administration recently sent a letter to health care professionals warning that patients taking these drugs should avoid invasive dental procedures.2

The drugs: Bisphosphonates work by inhibiting osteoclast-mediated bone resorption. They are often prescribed for use over long periods and in conjuction with chemotherapeutic agents or steroids.

It is unclear why the osteonecrosis (avascular necrosis) experienced seems to affect the jaw preferentially. It occurs, often after many months of using the drugs,3 in 1 patient in about 10 000.1 Possible risk factors include having a diagnosis of cancer; using corticosteroids, chemotherapy or radiation therapy; and having a comorbid condition, including poor oral hygiene, dental disease and infection (including osteomyelitis), anemia and coagulopathies.2 Although some affected patients notice no symptoms, others experience more serious signs and symptoms (see Box). Osteonecrosis of the jaw is rarely reported in patients who take bisphosphonates orally, including long-term users.3

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

What to do: Patients who are to receive intravenous bisphosphonates should be warned of this potential effect. If time permits before the drug therapy is initiated, a dental examination may detect and allow treatment of tooth or gum problems that could predispose a patient to osteonecrosis. Proper denture fit should be ensured and good dental hygiene reinforced. The oral hard and soft tissues of patients taking these drugs should be examined every 3 months or so. Invasive procedures that may require bone to heal, such as tooth extractions and bone biopsies, should be avoided if possible. When dental surgery is required, it is uncertain whether cessation of bisphosphonate therapy decreases the risk of necrosis. Prompt referral to a dentist or oral maxillofacial surgeon is recommended for patients with facial symptoms of osteonecrosis, although surgery in the affected area may exacerbate or prolong the condition. Conservative management includes culturing any lesions and using antibiotics as appropriate, and recommending an antiseptic oral rinse that contains chlorhexidine gluconate. Unfortunately, some affected patients ultimately require the resection of portions of their jaw.

Footnotes

  • Published at www.cmaj.ca on June 1, 2005.

References

  1. 1.↵
    Novartis Pharmaceuticals Co. Updated safety: possible relationship of Aredia (pamidronate disodium) and/or Zometa (zoledronic acid) with osteonecrosis of the jaw [letter to health care professionals]. Ottawa: Health Canada; Nov 2004. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/aredia_zometa_hpc_e.html (accessed 2005 May 26).
  2. 2.↵
    Novartis Pharmaceuticals Co. Important drug precaution for dental health professionals with patients being treated for cancer [letter to dentists]. Rockville (MD): US Food and Drug Administration; 2005 May 5. Available: www.fda.gov/medwatch/safety/2005/safety05.htm#zometa2 (accessed 2005 May 26).
  3. 3.↵
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (13)
CMAJ
Vol. 172, Issue 13
21 Jun 2005
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures
Eric Wooltorton
CMAJ Jun 2005, 172 (13) 1684; DOI: 10.1503/cmaj.050640

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures
Eric Wooltorton
CMAJ Jun 2005, 172 (13) 1684; DOI: 10.1503/cmaj.050640
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Oral health
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire